|  |  | P |
---|---|---|---|
Characteristics | Non-transplant (n= 67) | Transplant (n = 55) | Non-transplant vs transplant |
Gender, n (%) | Â | Â | 0.153 |
 Male | 34 (50.7) | 35 (63.6) |  |
 Female | 33 (49.3) | 20 (36.4) |  |
Age, years | Â | Â | 0.332 |
 Median (range) | 27 (9, 65) | 26 (3, 65) |  |
Hyperploidy, n (%) | 3 (4.5) | 3 (5.5) | 0.804 |
Hypoplodiy, n (%) | 1 (1.5) | 1 (1.8) | 0.888 |
Complex karyotype, n (%) | 4 (6.0) | 2 (3.6) | 0.553 |
iAMP 21a, n (%) | 1 (1.5) | 1 (1.8) | 0.888 |
ETV6-RUNX1, n (%) | 1 (1.5) | 0 (0) | 0.363 |
E2A-PBX1, n (%) | 1 (1.5) | 0 (0) | 0.363 |
MYC mutation, n (%) | 1 (1.5) | 0 (0) | 0.363 |
HOX11 mutation, n (%) | 1 (1.5) | 0 (0) | 0.363 |
KMT2A rearranged, n (%) | 3 (4.5) | 5 (9.1) | 0.306 |
BCR-ABL1, n (%) | 11 (16.4) | 11 (20.0) | 0.609 |
Ph like, n (%) | 1 (1.5) | 4 (7.3) | 0.109 |
IgH rearranged, n (%) | 1 (1.5) | 0 (0) | 0.363 |
IKZF1 mutation, n% | 3 (4.5) | 7 (12.7) | 0.098 |
Poor-risk cytogeneticsb, n (%) | 18 (26.9) | 21 (38.2) | 0.182 |
Good-risk cytogeneticsc, n (%) | 2 (3.0) | 2 (3.6) | 0.841 |
Primary refractory to chemotherapy, n (%) | 17 (25.4) | 21 (38.2) | 0.128 |
Total number of relapses before CAR-T | Â | Â | 0.405 |
 Median (range) | 1 (0, 6) | 1 (0, 3) |  |
Prior lines of therapy | Â | Â | 0.888 |
 Median (range) | 4 (2, 15) | 3 (2, 9) |  |
 Prior allo-HSCT, n (%) | 22 (32.8) | 3 (5.5) | < 0.001 |
 Extramedullary infiltration, n (%) | 9 (13.4) | 3 (5.5) | 0.141 |
Platelet count before CAR-T, 109/L | Â | Â | 0.339 |
 Median (range) | 130 (15, 412) | 140 (12, 389) |  |
PLT < 1*LLN before CAR-T, n (%) (n = 66 + 52) | 28 (42.4) | 15 (28.8) | 0.128 |
LDH > 1*ULN before CAR-T, n (%) (n = 66 + 52) | 26 (39.4) | 25 (48.1) | 0.345 |
Blast cells in bone marrow before CAR-T | Â | Â | 0.766 |
 Median (range) | 22.5% (0, 97.0%) | 16.0% (0, 90.0%) |  |
CAR-T cell dose, 106/kg | Â | Â | 0.853 |
 Median (range) | 3.0 (0.3, 25.0) | 5.0 (0.1, 30.4) |  |
Source of CAR-T cells, n (%) | Â | Â | 0.002 |
 Autologous | 44 (65.7) | 50 (90.9) |  |
 Recipient-derived allogenic | 15 (22.4) | 3 (5.5) |  |
 Donor-derived allogenic | 7 (10.4) | 0 (0) |  |
 Third-party | 1 (1.5) | 2 (3.6) |  |